AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06695286 — intervention group
Intervention type: OTHER
Intervention: Multimodal rehabilitation training at low intensity
Description: In Low Intensive Training patients received less than 900 minutes of training globally.~In our practice, a single outpatient session varies from 60 to 90 minutes, the number of sessions per cycle from 10 to 20, and the frequency from 2 days a week to 5 days a week. Irrespective of total course intensity, each session comprises at least 15 minutes of aerobic training (over ground or treadmill) and 10 minutes of flexibility and strengthening exercise. No less than 10 minutes of balance training, 10 minutes of overground training in dual tasks, and 15 minutes of occupational therapy are additionally delivered. The duration of the single training components in each session may increase according to the patients' functioning profiles, requesting a more intensive practice of gait, balance or trunk alignment or a focused training of arm dexterity or basic ADL.
Study NCT01851226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hands-on ERCP training.
Description: The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
Study NCT02798952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B Kinder
Description: Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
Study NCT01420003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: 3 per study
Study NCT00715442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg by mouth daily for 28 consecutive days
Study NCT00715442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
Study NCT01420003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsil Biopsy
Description: Optional upon completion of study
Study NCT00563563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB32
Description: All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
Study NCT00563563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ancillary therapy
Description: During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
Study NCT04394832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief cognitive intervention
Description: See the information provided in the experimental arm description.
Study NCT01306994 — intervention group
Intervention type: OTHER
Intervention: Lactate, Glucose, and Adenosine Triphosphate Blood Levels
Description: Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
Study NCT01306994 — intervention group
Intervention type: PROCEDURE
Intervention: Physiological Stress Test
Description: During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
Study NCT04271280 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: This is a non-interventional study.
Study NCT01306994 — intervention group
Intervention type: OTHER
Intervention: Functional Enquiry Form
Description: Evaluated before clinical examination, it is a checklist of medical problems.
Study NCT02176967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound
Study NCT01306994 — intervention group
Intervention type: OTHER
Intervention: Strength, Joint ROM, Girth and Length Measurements
Description: Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
Study NCT01306994 — intervention group
Intervention type: OTHER
Intervention: Study Physical Examination
Description: Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
Study NCT01306994 — intervention group
Intervention type: OTHER
Intervention: Observational Gait Analysis
Description: Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
Study NCT01306994 — intervention group
Intervention type: OTHER
Intervention: Mental Health Interview
Description: Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
Study NCT03098771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the cell transplantation group
Description: Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
Study NCT03098771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the control group
Description: Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
Study NCT00735358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacrylate
Description: Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
Study NCT03495440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center Sessions
Description: Program to support relationships and communication between parents and typically developing adolescent siblings of individuals with intellectual and/or developmental disabilities.
Study NCT03495440 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: At-home
Description: Self-study resources paired with regular contact with study personnel.
Study NCT00735358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Description: Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
Study NCT02973672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101
Description: 4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
Study NCT01417286 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Hypofractionated accelerated radiation therapy over 11 days
Study NCT03373786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG012
Description: RG012 in 0.3% sodium chloride
Study NCT02217735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing Intervention
Description: Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
Study NCT02217735 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Writing Intervention
Description: Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
Study NCT03042949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement
Description: Blood pressure measurement with a standard plethysmograph
Study NCT03042949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement with the new device
Description: Blood pressure measurement with the optical sensor, Elfor -1 device.
Study NCT05115318 — intervention group
Intervention type: DRUG
Intervention: Medical Cannabis
Description: Patients with GTS were assessed before, 4 and 12 weeks after Medical cannabis initiation for consumption habits, efficacy and side effect profile
Study NCT01158950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Drug: Tolcapone 200mg (single dose) administered at study visit
Study NCT01158950 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (200mg) administered at study visit
Study NCT01469104 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3 day fast
Description: Subjects will fast for 72 hours
Study NCT01469104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 day CHO-free diet
Description: Subjects will receive a carbohydrate-free diet for 72 hours
Study NCT02277132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil 25 mg three times daily orally from randomization until delivery
Study NCT02277132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets three times daily orally from randomization until delivery
Study NCT04399278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic Test: end-expiratory occlusion (EEO) test
Description: A set of respiratory and hemodynamic measurements (including cardiac output) will be recorded at each stage:~* T0: baseline.~* T1: At the end of the first EEO (15 sec or 30 sec)~* T2: 1 minute after completion of the first EEO. Return to baseline.~* T3: At the end of the second EEO (15 sec or 30 sec)~* T4: 1 minute after completion of the second EEO. Return to baseline.~* T5: Before the fluid challenge test (4 ml/kg of 0.9% saline over 5 min)~* T6: 1 minute after the end of the fluid challenge~A first set of measurements will be performed after intubation (before the surgical incision) and will be repeated, if necessary, in case of further decrease in stroke volume during surgery or in case of any clinical indication of volume expansion (i.e., arterial persistent hypotension, major hemorrhage, etc.).
Study NCT01933672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 once-daily
Description: Tablets, 300 mg once-daily with breakfast, 14-days
Study NCT01933672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319 split-dose
Description: tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
Study NCT01933672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin once-daily
Description: tablets, 100 mg once-daily with breakfast, 14-days
Study NCT03993743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD147-CART
Description: Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
Study NCT00814801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
Study NCT00814801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Description: Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
Study NCT00814801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Description: Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
Study NCT03089983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Participants will receive daily or weekly doses of oral methadone.
Study NCT03089983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.
Study NCT03089983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.
Study NCT03089983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Participants will be randomized to receive short course INH + RIF as TB treatment in prison for 12 weeks.
Study NCT03663933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression Only Conditioning
Description: E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -9 and -5, cyclophosphamide:5 mg/kg orally daily on days -9 through -2
Study NCT03663933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning
Description: E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2/day IV on days -11 and -7, cyclophosphamide:3 mg/kg orally daily on days -11 through -4 Busulfan IV, pharmokinetically dosed, on days -3 and -2.
Study NCT03663933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, Mesna: 25-50 mg/kg weight based dosing, Tacrolimus 0.02 mg/kg on days +5 through +90, and mycophenolate mofetil (MMF) 15 mg/kg on days +5 through +25
Study NCT03663933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSC
Description: Stem cell transplant
Study NCT02890069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD1 antibody
Study NCT02890069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Study NCT02890069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT02890069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study NCT02890069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBM076
Study NCT02890069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Study NCT02577783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone
Description: doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
Study NCT02577783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAD regimen: bortizomib, dexamethasone and doxorubicin
Description: doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
Study NCT05959187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pharmacogenomic testing
Description: Pharmacogenomic testing has emerged as a promising diagnostic tool, allowing clinicians to guide the selection and dosage of antidepressant medications. In theory, pharmacogenomic testing may provide improved drug selection and dosing strategies for patients with genetic alterations related to drug response
Study NCT03125447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speed and accuracy answer to visual stimuli
Description: A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
Study NCT03125447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: speed and accuracy answer to visual stimuli
Description: A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
Study NCT02889107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personal frequency modulated systems
Description: patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
Study NCT04001062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Fixation
Description: For both scissoring and non-scissoring injuries surgical fixation by either pinning, dorsal plate, or lag screws will be considered. This will be determined by surgeon expertise at the time of surgical fixation. Postoperative, a volar short arm splint and immediate AROM at full range with buddy taping to adjacent digit will be indicated. Transition to removable short arm splint at week 2 after suture removal. No strengthening until clinical union.
Study NCT04001062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Operative Management
Description: 1. For non-scissoring injuries: Placement of short-arm cast; immediate AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union.~2. For scissoring injuries: Closed reduction in clinic/ER and placement of short-arm cast; immediate full range AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of \<2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union
Study NCT02851654 — intervention group
Intervention type: DEVICE
Intervention: Infrared oculography
Description: The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
Study NCT02896725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keratin dressings
Description: Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
Study NCT02896725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care dressings
Description: Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
Study NCT04385407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Simeprevir + Ribavirin
Study NCT04432220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation group(Apixaban group)
Description: Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
Study NCT04299087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy using a magnet to target and stimulate certain areas of the brain.
Study NCT04299087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No application of rTMS
Study NCT02761525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: silver nanoparticles
Description: Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
Study NCT02761525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
Study NCT00767260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BM-MNC+HOT
Description: Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
Study NCT00767260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BM-MNC
Description: Autologous Bone Marrow Mononuclear cell Infusion
Study NCT00767260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HOT
Description: Hyperbaric Oxygen Therapy
Study NCT00767260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMT
Description: hypoglycemic drugs or exogenous insulin
Study NCT01836601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-centered nighttime communication bundle
Study NCT03312855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revacept 80 mg
Description: single dose, intravenous application of 80 mg Revacept
Study NCT03312855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revacept 160 mg
Description: single dose, intravenous application of 180 mg Revacept
Study NCT03312855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose, intravenous application of Placebo solution
Study NCT05751005 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Peptides vs. Placebo
Description: Participants were randomized into one of three treatment groups.